Texas Doc Down: DEA Strips Prescription Power Immediately
Published Date: 7/9/2025
Notice
Summary
Dr. Andrew Jones from Texas lost his state permission to handle controlled substances, so the DEA has officially taken away his registrations to prescribe or manage these drugs. This means he can no longer legally work with controlled substances in Texas, effective immediately. If you’re a patient or partner, this change affects how controlled meds are handled starting now, with no money or license privileges for Dr. Jones.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Revokes Dr. Andrew Jones’s Registrations
The DEA revoked Andrew Jones, M.D.'s Certificates of Registration Nos. FJ3614826 and FJ9984154, so he is no longer authorized by DEA to prescribe, administer, dispense, or otherwise handle controlled substances in Texas. The revocation is effective August 8, 2025.
DEA Denies Dr. Jones’s Pending and New Texas Applications
The DEA denied any pending applications by Andrew Jones, M.D. to renew or modify Certificates of Registration Nos. FJ3614826 and FJ9984154, and denied any other pending application by him for additional registration in Texas. That denial is effective August 8, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13821 — Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13580 — Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
Previous / Next Documents
Previous: 2025-12701 — John Hanley, P.A.; Decision and Order
John Hanley, P.A. from New Mexico lost his DEA registration because he no longer has the state permission to handle controlled substances. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his certificate starting in 2025. This means John can’t legally prescribe or manage controlled drugs anymore, affecting his medical practice and patients.
Next: 2025-12703 — Hayriye Gok, M.D.; Decision and Order
Dr. Hayriye Gok from Philadelphia lost her DEA registration because she no longer has permission to handle controlled substances in Pennsylvania. She didn’t ask for a hearing after being notified, so the DEA officially revoked her registration. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately.